An investigation on behalf of investors in Steadymed Ltd (NASDAQ:STDY) shares over potential wrongdoing at Steadymed Ltd was announced and NASDAQ:STDY stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 11/06/2017 -- An investigation was announced for investors in shares of Steadymed Ltd (NASDAQ:STDY) concerning possible breaches of fiduciary duties by certain officers and directors at Steadymed Ltd.
Investors who purchased shares of Steadymed Ltd (NASDAQ:STDY) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
The investigation by a law firm concerns whether certain Steadymed directors breached their fiduciary duties.
On August 31, 2017, Steadymed Ltd announced receipt of a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") concerning the Company's New Drug Application ("NDA") for Treyvent, a pulmonary arterial hypertension treatment. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review. Shares of Steadymed Ltd (NASDAQ:STDY) declined to $3.35 per share on August 31, 2017.
Those who purchased shares of Steadymed Ltd (NASDAQ:STDY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels